Secondly, the radiotherapy community also expects the results of studies assessing the effectiveness of systemic treatment in BCBM, especially in HER2+ breast cancer, because small molecules with good penetration of the BBB may change the paradigm and replace intracranial radiotherapy or significantly delay its use. Here, ERBB2 is linked to breast carcinoma.